
        <!DOCTYPE html>
        <html>
        <head>
            <title>Immunocore Holdings plc (IMCR) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Immunocore Holdings plc (IMCR)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">7</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">6</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.47</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=065d3bd2b2359a15da5b3d0762f8a615d917683cc0f0ac3781c6d23a179a7c2f" target="_blank" rel="noopener noreferrer">Biogen Begins Phase III Felzartamab Study for Third Kidney Disease</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.38
                                </span>
                            </div>
                            <div class="article-summary">BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=55e76d9338e07f1a672b69e3f297957f0fb58e9b753292c157b4fd1e2ddf323e" target="_blank" rel="noopener noreferrer">Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.37
                                </span>
                            </div>
                            <div class="article-summary">Er-Kim will distribute KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in accordance with applicable local regulations in the a...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=feccf62b510b5b49b38815de9f0898ac9373db0f40db6d584e45cda9bd19b720" target="_blank" rel="noopener noreferrer">Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.51
                                </span>
                            </div>
                            <div class="article-summary">Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=a0391bc17c6f2a1c34ba75a1da8888cab36c64df16c111a59f859141f5481153" target="_blank" rel="noopener noreferrer">Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Kamada (KMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2e8a27abb919fb13ee91b1afc9ef3f41427bdaf837f314f04a076c810c87d2a1" target="_blank" rel="noopener noreferrer">FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-24</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.87
                                </span>
                            </div>
                            <div class="article-summary">FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=888e169590425d0b04646e475e4a44c603e3ef61b4a9462821aeb378d6af90db" target="_blank" rel="noopener noreferrer">Tracking Baker Brothers Portfolio - Q1 2025 Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-17</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Baker Brothersâ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and high-conviction strategies....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6fc0923de665aaeccb99bfd22f33e2d102b5761eda9cacd04d46d1d4242a057a" target="_blank" rel="noopener noreferrer">Delcath Systems: Growing Fast, But Business Model Is Fragile</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-12</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Delcath's HEPZATO sees rapid sales growth but faces a small market, competition, and moderate efficacy gains....</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        